EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comprehensive functional characterization of complement factor I rare variant genotypes identified in the SCOPE geographic atrophy cohort

Thomas M Hallam, Anneliza Andreadi, Scott J Sharp, Vicky Brocklebank, Emanuela Gardenal, Anna Dreismann, SCOPE Study Group, Andrew J Lotery, Kevin J Marchbank, Claire L Harris, Amy V Jones, David Kavanagh

Journal of Biological Chemistry · 2024

DOI: 10.1016/j.jbc.2024.107452 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2024. Verfasst von Thomas M Hallam und 11 weiteren Autor:innen. Beteiligte Einrichtung: Gyroscope Therapeutics Limited, A Novartis Company, London, UK. Electronic address: thomas.hallam@novartis.com. Hauptthemen laut MEDLINE: Complement Factor I, Geographic Atrophy, Genotype, Complement C3b. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rare variants (RVs) in the gene encoding the regulatory enzyme complement factor I (CFI; FI) that reduce protein function or levels increase age-related macular degeneration risk. A total of 3357 subjects underwent screening in the SCOPE natural history study for geographic atrophy secondary to age-related macular degeneration, including CFI sequencing and serum FI measurement. Eleven CFI RV genotypes that were challenging to categorize as type I (low serum level) or type II (normal serum level, reduced enzymatic function) were characterized in the context of pure FI protein in C3b and C4b fluid phase cleavage assays and a novel bead-based functional assay (BBFA) of C3b cleavage. Four variants predicted or previously characterized as benign were analyzed by BBFA for comparison. In all, three variants (W51S, C67R, and I370T) resulted in low expression. Furthermore, four variants (P64L, R339Q, G527V, and P528T) were identified as being highly deleterious with IC50s for C3b breakdown >1 log increased versus the WT protein, while two variants (K476E and R474Q) were ∼1 log reduced in function. Meanwhile, six variants (P50A, T203I, K441R, E548Q, P553S, and S570T) had IC50s similar to WT. Odds ratios and BBFA IC50s were positively correlated (r = 0.76, p < 0.01), while odds ratios versus combined annotation dependent depletion (CADD) scores were not (r = 0.43, p = 0.16). Overall, 15 CFI RVs were functionally characterized which may aid future patient stratification for complement-targeted therapies. Pure protein in vitro analysis remains the gold standard for determining the functional consequence of CFI RVs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Complement Factor IGeographic AtrophyGenotypeComplement C3bHumansFemaleMaleAgedCohort StudiesMacular DegenerationMiddle Aged

Stichwörter der Autor:innen

C3 glomerulopathy(C3G)age-related macular degeneration (AMD)atypical hemolytic uremic syndrome (aHUS)complementcomplement factor Icomplement systemenzyme mutationinnate immunityretinal degeneration

Substanzen

Complement Factor IComplement C3bCFI protein, human

Autor:innen und Institutionen

  • Gyroscope Therapeutics Limited, A Novartis Company, London, UK. Electronic address: thomas.hallam@novartis.com.
  • Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK; National Renal Complement Therapeutics Centre, Royal Victoria Infirmary, Newcastle up…
  • Gyroscope Therapeutics Limited, A Novartis Company, London, UK.
  • Clinical and Experimental Sciences, Faculty of Medicine, University Hospital Southampton, University of Southampton, Southampton, UK.
  • Gyroscope Therapeutics Limited, A Novartis Company, London, UK; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.

Förderung

  • Wellcome Trust
  • Medical Research Council

Zitieren

APA

Hallam, T. M., Andreadi, A., Sharp, S. J., Brocklebank, V., Gardenal, E., Dreismann, A., SCOPE Study Group, Lotery, A. J., Marchbank, K. J., Harris, C. L., Jones, A. V., & Kavanagh, D. (2024). Comprehensive functional characterization of complement factor I rare variant genotypes identified in the SCOPE geographic atrophy cohort. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2024.107452

Vancouver

Hallam TM, Andreadi A, Sharp SJ, Brocklebank V, Gardenal E, Dreismann A, et al. Comprehensive functional characterization of complement factor I rare variant genotypes identified in the SCOPE geographic atrophy cohort. Journal of Biological Chemistry. 2024. doi:10.1016/j.jbc.2024.107452

BibTeX
@article{Hallam2024,
  author = {Hallam, Thomas M and Andreadi, Anneliza and Sharp, Scott J and Brocklebank, Vicky and Gardenal, Emanuela and Dreismann, Anna and SCOPE Study Group, SCOPE Study Group and Lotery, Andrew J and Marchbank, Kevin J and Harris, Claire L and Jones, Amy V and Kavanagh, David},
  title = {Comprehensive functional characterization of complement factor I rare variant genotypes identified in the SCOPE geographic atrophy cohort},
  journal = {Journal of Biological Chemistry},
  year = {2024},
  doi = {10.1016/j.jbc.2024.107452}
}
Kostenlos starten →